Ampio Pharmaceuticals(AMPE)
$0.180.00 (0.00%)
AMPE
Ampio Pharmaceuticals financials statements
$0.18
At close:0.00 (0.00%)
Want to see AMPE full AI Analyst Report?
Ampio Pharmaceuticals (AMPE) Ratios
505 Followers
Ampio Pharmaceuticals Ratios
AMPE's free cash flow for Q4 2023 was $-2.31M. For the 2023 fiscal year, AMPE's free cash flow was increased by $0.00 and operating cash flow was $-2.31M. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.41 | 11.18 | 6.96 | 10.08 | 1.93 |
| Quick Ratio | 2.41 | 11.18 | 6.94 | 9.94 | 1.93 |
| Cash Ratio | 1.72 | 10.61 | 6.62 | 9.46 | 1.52 |
| Solvency Ratio | -3.53 | -8.50 | -1.38 | -2.74 | -1.64 |
| Operating Cash Flow Ratio | -3.60 | -17.72 | -2.75 | -8.03 | -3.59 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -111.79 | -52.38 | 0.00 | -59.39 |
| Net Current Asset Value | $ 3.36M | $ 11.53M | $ 24.09M | $ 13.13M | $ 692.00K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.06 | 0.03 | 0.05 | 0.10 |
| Debt-to-Equity Ratio | 0.08 | 0.07 | 0.04 | 0.07 | 0.23 |
| Debt-to-Capital Ratio | 0.08 | 0.06 | 0.04 | 0.06 | 0.19 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 |
| Financial Leverage Ratio | 1.71 | 1.15 | 1.42 | 1.31 | 2.17 |
| Debt Service Coverage Ratio | 0.00 | -80.89 | -42.35 | 0.00 | -21.83 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -241.25 |
| Debt to Market Cap | 0.00 | 0.07 | 0.00 | 0.00 | 0.02 |
| Interest Debt Per Share | 0.34 | 1.44 | 1.80 | 2.10 | 3.26 |
| Net Debt to EBITDA | 0.46 | 0.51 | 2.05 | 1.11 | 0.41 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 90.69% | 80.15% | 83.01% | 100.38% | 73.37% |
| Return on Assets (ROA) | -150.49% | -120.23% | -43.98% | -69.47% | -97.35% |
| Return on Equity (ROE) | -256.90% | -138.58% | -62.58% | -90.76% | -211.55% |
| Return on Capital Employed (ROCE) | -283.27% | -164.42% | -61.04% | -75.24% | -191.17% |
| Return on Invested Capital (ROIC) | -252.47% | -81.73% | -43.87% | -74.24% | -115.63% |
| Return on Tangible Assets | -150.49% | -120.23% | -43.98% | -69.47% | -97.35% |
| Earnings Yield | -520.49% | -637.62% | -15.03% | -5.78% | -16.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.33 | 21.43 | 2.56 | 6.33 | 8.42 |
| Inventory Turnover | 0.00 | 0.00 | 15.19 | 4.43 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1095.00 | -17.03 | -118.44 | 24.79 | -43.33 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 24.02 | 82.42 | 0.00 |
| Days of Payables Outstanding | 1095.00 | 17.03 | 142.46 | 57.63 | 43.33 |
| Operating Cycle | 0.00 | 0.00 | 24.02 | 82.42 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -10.59 | -37.93 | -21.21 | -25.56 | -32.45 |
| Free Cash Flow Per Share | -10.59 | -37.93 | -21.35 | -25.67 | -32.50 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -145.25 | -233.79 | -699.23 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -145.25 | -233.79 | -699.23 |
| Operating Cash Flow Coverage Ratio | -31.26 | -26.31 | -11.80 | -12.18 | -10.47 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -516.39% | -824.60% | -12.49% | -5.38% | -18.68% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.19 | -0.16 | -6.65 | -17.29 | -6.05 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.49 | 0.22 | 4.16 | 15.69 | 12.80 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.19 | -0.12 | -8.01 | -18.58 | -5.35 |
| Price-to-Operating Cash Flow Ratio | -0.19 | -0.12 | -8.06 | -18.66 | -5.36 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.00 | 0.19 | -0.31 | 0.05 |
| Enterprise Value Multiple | 0.26 | 0.40 | -5.06 | -17.74 | -6.30 |
| Enterprise Value | -2.16M | -9.29M | 80.90M | 258.69M | 77.42M |
| EV to EBITDA | 0.26 | 0.40 | -5.06 | -17.74 | -6.30 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.25 | 0.44 | -5.70 | -17.49 | -5.03 |
| EV to Operating Cash Flow | 0.25 | 0.44 | -5.74 | -17.56 | -5.03 |
| Tangible Book Value Per Share | 4.15 | 21.17 | 41.07 | 30.39 | 13.59 |
| Shareholders’ Equity Per Share | 4.15 | 21.17 | 41.07 | 30.39 | 13.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.48 | 0.27 | -0.04 | 0.36 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -10.67 | -29.33 | -25.70 | -27.59 | -28.75 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.67 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.99 | 1.29 | 0.83 | 0.93 | 1.13 |
Currency in USD

